In a number of cases, liver metastases or concomitant hepatitis are the cause of organ failure. Changes in biochemical parameters, indirectly reflecting the degree of functional damage to the liver, are not an absolute contraindication for systemic treatment taking into account the correction of doses necessary for a number of cytotoxic drugs, according to the Internet edition for girls and women aged 14 to 35 Pannochka. net In cases with a violation of the outflow of bile due to compression of the choledochus and / or the bile ducts, the drug treatment is possible after the establishment of adequate drainage of the bile ducts. Local intrahepatic cholestasis is complicated by focal cholestatic hepatitis with outcome in cholangiosclerosis. Active anti-inflammatory therapy with the use of glucocorticoids reduces the manifestations of nonspecific inflammation and often leads to symptomatic improvement and a temporary decrease in the concentration of serum transaminases, bilirubin.

The potential for nonspecific, so-called hepatoprotective therapy is small, but the use of ademethionine (heptral), ursodeoxycholic acid preparations (ursosan, ursofalk), methyluracil, Essentiale, carlosil.

With a progressive rapid deterioration of the patient's objective condition, a violation of the albuminous function of the liver (rapid decrease in the concentration of total protein and plasma albumin, prothrombin, fibrinogen), chemotherapy is not justified. Progressive liver failure is an absolute contraindication to antitumor therapy.

health. sumy. ua.